The prescription digital therapeutics (PDT) category has had a difficult decade. Pear Therapeutics, the most prominent first-wave PDT developer, filed for bankruptcy in April 2023 despite holding three FDA-cleared products (reSET for substance use disorder, reSET-O for opioid use disorder, Somryst for insomnia) and substantial venture funding. The collapse was widely framed as a failure of business model rather than of clinical product. The clinical evidence for FDA-cleared PDTs is real. The reimbursement infrastructure to actually pay for them was, until recently, not.

That changed on January 1, 2025, when the Centers for Medicare and Medicaid Services (CMS) implemented three new HCPCS Level II codes specifically for digital mental health treatment devices. G0552 covers the supply of the device and initial education and onboarding, per course of treatment. G0553 covers the first 20 minutes of monthly treatment management services. G0554 covers each additional 20 minutes of management beyond the first.

This is the most consequential single regulatory change in the PDT space in five years, and most of the industry coverage has misread what it does and what it does not do. The codes are not a general PDT reimbursement category. They are a narrow carve-out for one specific subcategory of digital therapeutic, tied to one specific FDA classification, structured in a way that creates both new commercial opportunities and new commercial constraints.

This piece walks through what the codes actually cover, what they exclude, and why the narrow scope is reshaping the strategic positioning of every digital health company in mental health.

What the codes actually cover

The G0552-G0554 codes apply specifically to digital therapeutics cleared or approved by the FDA under 21 CFR 882.5801, which is the regulatory classification for “computerized behavioral therapy for psychiatric disorders.” This is a specific FDA category, not a general digital health category. To bill under G0552-G0554, a product must:

Be FDA-cleared or FDA-approved under 21 CFR 882.5801 specifically. Other FDA classifications for digital products (general wellness, clinical decision support, monitoring-only software) do not qualify, regardless of how similar the product looks to a consumer or a prescriber.

Be prescribed by a Medicare-enrolled provider as part of a documented behavioral therapy treatment plan. The codes are explicitly framed as augmenting a behavioral therapy plan, not replacing one. A digital therapeutic prescribed as a standalone intervention does not fit the billing structure.

Be associated with measurable patient engagement that can be reported back to the prescriber. The G0553 code requires that the provider review information related to the patient’s use of the device and conduct at least one interactive communication with the patient or caregiver during the billing month. Products that lack the data infrastructure to support this reporting cannot be billed under the codes at all.

The Medicare reimbursement rates attached to the codes are modest. CMS’s 2025 Physician Fee Schedule set the rates at levels that cover the cost of provider time spent on the patient’s digital therapeutic management; they do not, on their own, support a robust direct-to-consumer business model. The codes are designed to embed PDTs into existing provider workflows, not to create a standalone reimbursement engine for the products.

What the codes exclude

The codes do not apply to: general wellness apps, even if marketed for mental health adjacencies; digital therapeutics for non-psychiatric indications (cardiovascular, metabolic, oncologic); telepsychiatry platforms that deliver human-provided care via digital channels (these have their own separate reimbursement under telehealth codes); FDA-cleared devices in other classifications even if they target psychiatric conditions.

This is the structural point most industry coverage misses. The G-codes are not “the PDT category in Medicare.” They are the digital-cognitive-behavioral-therapy category in Medicare. A company building a digital therapeutic for, say, post-stroke depression that does not fit the 21 CFR 882.5801 classification has no Medicare reimbursement pathway, even if the product is clinically excellent.

The narrow scope was a deliberate choice. The Cures Act 2.0 and subsequent industry advocacy had pushed for broader PDT reimbursement; the final 2025 framework was more targeted. The industry trade organization (the Digital Therapeutics Alliance) has been clear in its public statements that the G-codes are a starting point rather than the final framework.

Who actually qualifies

The list of FDA-cleared digital therapeutics qualifying for billing under G0552-G0554 is short. As of the most recent CMS guidance, qualifying products include digital cognitive behavioral therapy applications cleared under the 21 CFR 882.5801 pathway. The category includes products from Akili Interactive (EndeavorOTC for ADHD-related cognitive function, EndeavorRx for pediatric ADHD), Big Health (Sleepio for insomnia, Daylight for anxiety), Click Therapeutics (Rejoyn for major depressive disorder, FDA-cleared in 2024), and a handful of smaller developers.

Even within this short list, billing is not automatic. Each product’s manufacturer must register the product with CMS for billing purposes, and the provider must verify that the specific product is currently billable under the G-codes for the specific indication. This bureaucratic layer is real and has slowed adoption.

For the field’s economics, the implication is that the PDT category is bifurcating into two tiers. Tier one: products that fit 21 CFR 882.5801 and have engaged with the CMS billing infrastructure. These have a Medicare reimbursement pathway, however narrow. Tier two: everything else. The second tier is much larger than the first.

The commercial implications

For investors and operators tracking the digital mental health space, the G-codes create three structural shifts worth pricing in.

First, the value of FDA clearance under 21 CFR 882.5801 specifically has increased. Companies with products in this regulatory pathway have a reimbursement asset that companies with products in adjacent FDA categories do not. This creates an incentive for companies to design new products specifically for this regulatory pathway, even when other classifications might offer faster clearance or broader labels.

Second, the consolidation in the PDT space is likely to accelerate. The bureaucratic infrastructure required to manage CMS billing (provider education, claims processing, prior authorization handling, denial management) is substantial. Small developers without the operational capacity to manage it will struggle to monetize their products even when billing is technically available. The advantage flows to operators with scale: larger digital health platforms that can integrate PDTs as a service offering, or pharmaceutical companies with existing reimbursement infrastructure that can absorb the PDT category as a product extension.

Third, the strategic positioning of telehealth platforms (Teladoc, Talkspace, the surviving direct-to-consumer mental health platforms) shifts in a specific direction. These platforms have provider networks, billing infrastructure, and patient engagement systems already built. Integrating FDA-cleared PDTs into their provider workflow is a meaningfully easier operational lift than building those systems from scratch as a pure PDT company. The telehealth platforms have a structural advantage in capturing the value the G-codes create, even though the codes were not designed with them in mind.

The Pear Therapeutics bankruptcy looks different in retrospect under this framing. Pear had clinically validated products but not the operational infrastructure to extract value from them once reimbursement pathways became available. The companies positioned to succeed under the new framework are not necessarily the ones with the best products. They are the ones with the operational capacity to bill effectively for products that fit the regulatory criteria.

What to watch in the next 12 to 24 months

Three near-term inflection points will determine how the PDT category evolves.

The first is whether CMS expands the G-code framework beyond psychiatric indications. The Digital Therapeutics Alliance has advocated for analogous codes covering cardiometabolic and oncologic digital therapeutics. The 2027 Medicare Physician Fee Schedule (proposed in mid-2026, finalized in late 2026) will be the first signal of whether CMS is moving in this direction. If it expands, the PDT category broadens substantially. If it does not, the psychiatric-only carve-out remains a permanent feature of the market structure.

The second is private payer adoption. Medicare reimbursement is necessary but not sufficient; the commercial market for PDTs depends on commercial health plans covering the same codes. Aetna, UnitedHealthcare, Anthem, and Cigna have moved at different speeds on PDT coverage, with substantial variation in prior authorization requirements and approved product lists. The 2026 employer benefit renewal cycle (typically negotiated in Q3 2026 for January 2027 effective dates) will reveal whether commercial coverage is converging or fragmenting further.

The third is the FDA’s posture on the 21 CFR 882.5801 pathway itself. The classification was created in 2017 and has been refined over subsequent guidance. A more stringent FDA posture (requiring more clinical evidence for clearance, longer review timelines, narrower indications) would slow the supply of new products into the category. A more permissive posture would accelerate it. The FDA’s 2026 medical device program guidance, expected later this year, will be the relevant signal.

The category is not yet what its 2018-era proponents hoped it would be. It is, however, structurally further along than the Pear bankruptcy framing suggested. The G-codes are the foundation. What gets built on top of them in the next two years will determine whether prescription digital therapeutics become a real category or remain a permanent niche.